Avecho Biotechnology Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVE.AX research report →
Price Chart
About the company
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations.
- CEO
- Paul Gavin
- IPO
- 1993
- Employees
- 9
- HQ
- Clayton, VIC, AU
Get TickerSpark's AI analysis on AVE.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $81.14M
- P/E
- -15.00
- PEG
- 0.15
- P/S
- 65.55
- P/B
- 46.13
- EV/EBITDA
- -13.04
- Div Yield
- 0.00%
- Gross Margin
- 60.70%
- Op Margin
- -485.09%
- Net Margin
- -248.73%
- ROE
- -258.19%
- ROIC
- -64.50%
Latest fiscal year · YoY change
- Revenue
- $1.24M+9.2%
- Gross Profit
- $751.29K+11.8%
- Op Income
- $-6,004,301
- Net Income
- $-4,416,623-41.5%
- EPS
- $-0.00-40.0%
- OCF Growth
- +127.8%
- FCF Growth
- +127.8%
- 52W High
- $0.03
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.01
- Beta
- 1.11
- RSI (14)
- 54
- Avg Volume
- 12.48M
No earnings-call transcripts are available for AVE.AX yet.
- Free Float
- 82.3%
- Shares Outstanding
- 3.86B
- Float Shares
- 3.18B
Our AVE.AX coverage
Recent articles, reports, and earnings notes.
No research on AVE.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVE.AX report →Positive interim analysis advances Avecho Phase III insomnia program
gurufocus.com · Jun 29
Avecho completes treatment phase for Phase III insomnia trial interim analysis
proactiveinvestors.com · May 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.